IsoRay (ISR) Announces Presentation of Positive Cesium-131 Brachytherapy Data at SNO Conference
- Wall Street swoons on rising Treasury yields, growing inflation worries
- Micron (MU) Stock Falls Following Q4 Beat, But Guidance Miss
- Sherwin-Williams (SHW) Stock Falls on Q3, FY20 Warning
- Brent dips after topping $80 a barrel, highest since Oct 2018
- Ford (F) Stock Soars on $11.4 Billion EV Partnership with Battery Maker SK Innovation (SKOVF)
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
IsoRay Inc. (NYSE: ISR) announced David G. Brachman, MD, FACRO, Director of Radiation Oncology, Barrow Neurological Institute, and Clinical Professor of Radiation Oncology, University of Arizona College of Medicine-Phoenix, presented the findings of a prospective trial entitled: "Prospective trial of surgery and permanent intraoperative brachytherapy (S+BT) using a modular, biocompatible radiation implant for recurrent aggressive meningiomas," at the Society of Neuro-Oncology Conference on Meningioma, Toronto, Canada.
Highlights of the presentation included:
- The study treatment involved a new means of delivering Cesium-131 brachytherapy to the brain, with the seeds embedded in collagen tiles and applied directly to the brain tissue after the tumor was removed (the GammaTile approach, which is not commercially available).
- The trial included 16 patients and 20 tumors.
- The patients in this study had recurrences of tumor after prior surgery and external beam radiation treatment and were considered by their physicians to be at an increased risk for additional recurrence.
- 95% of the treated tumors had no radiographic evidence of regrowth of tumor at the operative site (local control). The incidence of radiation side effects to the brain – a problem in previous attempts to perform brain brachytherapy – occurred in only two of the 20 treatments.
Dr. Brachman stated, "These are aggressive meningiomas that have recurred in patients despite previous surgery and radiation. These tumors pose a serious challenge to physicians due to their presence in the brain and the failure of prior treatments. Use of the Cesium-131 tiles, which were able to be implanted very quickly at the time of surgery, and starting radiation therapy at the time of resection as opposed to weeks after resection when using external beam radiation were advantages of our novel approach. We are seeing 95% local control of the treated tumors in our study using surgery and Cesium implants. In addition, we observed a very low rate of radiation injury, which has been a major concern in the past, for patients who have undergone multiple treatments for their brain tumors."
Tom LaVoy, CEO of IsoRay, Inc., stated, "We are encouraged to see this preliminary response to these challenging cancers. We are pleased Dr. Brachman had the opportunity to present his findings at such a prestigious forum of his peers."
Dr. Brachman concluded, "While we look forward to a future where systemic therapies are available for aggressive meningioma, our team believes the GammaTile approach using Cesium-131 offers a promising treatment option for patients."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IsoRay (ISR) Announces American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Cesium-131
- Amazon (AMZN) Games Launches New World
- Adial Pharmaceuticals (ADIL) Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!